To investigate the feasibility of using MMR and DDR genes in predicting the efficacy of ICI in diverse cancer types, we analyzed the mutation rates of 6 MMR genes (Supplementary Table S6) and 21 DDR genes (including TP53) (Supplementary Table S7) in 22 cancer types in all 39,631 patients. The gene discussed is DDR1; the disease is cancer.